🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

Prognostic Role of Inhibitor of Apoptosis Protein Overexpression on Recurrence Rate in Cervical Cancer

Recruitingn/aAges 18 Years - anyFemaleCentre Hospitalier Universitaire de Nīmes
NCT06147960 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

Overexpression of inhibitors of apoptosis proteins (IAPs) in patients treated for locally advanced cervical cancer with exclusive radio-chemotherapy may have a prognostic role on the local recurrence rate at 24 months.

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: * Patients treated with the exclusive radio-chemotherapy combination for locally advanced cervical carcinoma (stage Ib-IVb according to FIGO classification). * Patients aged ≥ 18 years. * Patients with a minimum of 2 years post-treatment follow-up. * Patients for whom the initial biopsy specimen (before treatment) is available. * Patients who have not indicated that they do not wish to participate in the study. * Patients affiliated to or benefiting from a health insurance scheme. Exclusion Criteria: * Patients under court protection, guardianship or curatorship.
💊

What it tests

  • Immunohistochemistry
📍

Where

1 site
CHU de Nîmes
Nîmes, France
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy